Condition

AML (Acute Myelogenous Leukemia) clinical trials and research

• 13Clinical trials
• 5Countries

Newest AML (Acute Myelogenous Leukemia) clinical trials

All recruiting trials (13)

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• Sulforaphane to speed blood‑cell recovery after long‑frozen cord‑blood transplant

  This trial tries sulforaphane to see if it helps adults with high‑risk AML, ALL, or MDS recover blood cells faster after receiving cord blood units frozen for 10 years or more.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjing · NCT07297576

• Venetoclax blood levels and treatment toxicity during hypomethylating-agent combinations for AML in remission

  This study will see if venetoclax blood levels are linked to side effects in people with AML who are in remission and receiving hypomethylating agents plus venetoclax.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT07254312

• Therapy plan for children with Down syndrome and acute myeloid leukemia in Russia

  This trial will test a standardized four-course chemotherapy program for children (0–18) with AML and Down syndrome in Russia to try to improve survival and reduce treatment side effects.

  Recruiting Phase 3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT07232134

• Donor-derived γδ T cell therapy for MRD-positive AML after stem-cell transplant

  This trial tests whether giving donor-derived γδ T cells can help adults with MRD-positive AML after an allogeneic stem-cell transplant.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Beijing · NCT07126782

• WBC100 capsules for adults with relapsed or refractory acute myeloid leukemia

  This trial will test whether taking WBC100 capsules once daily is safe and can help induce remission in adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 Hangzhou Weben Pharma Co., Ltd · Hangzhou, Zhejiang · NCT07014449

• Using CAR-T cell therapy for treating relapsed and refractory blood cancers

  This study is testing a new CAR-T cell therapy to see if it can help people with tough-to-treat blood cancers like lymphoma and leukemia feel better.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT06911710

• Observing gut health in children with leukemia

  This study looks at how leukemia treatment affects gut health and recovery in children aged 0-16 to see if nutrition plays a role in their healing process.

  Recruiting Great Ormond Street Hospital for Children NHS Foundation Trust · London · NCT06899581

• Targeting the immune environment in Acute Myeloid Leukemia

  This study is testing how the bone marrow environment affects treatment outcomes in people with Acute Myeloid Leukemia who are receiving azacitidine and venetoclax, to see if understanding this can improve immunotherapy.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06874257

• Post-transplant cyclophosphamide strategies to prevent graft-versus-host disease after mismatched unrelated donor stem cell transplant

  This platform tests whether adding different drug combinations with post-transplant cyclophosphamide prevents graft‑versus‑host disease better than the standard regimen for adults getting mismatched unrelated donor peripheral blood stem cell transplants for blood cancers.

  Recruiting at 13 sites Phase 2 Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 12 other locations · NCT06859424

• Immunotherapy using modified NK cells for treating relapsed or refractory AML

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Acute Myeloid Leukemia feel better and achieve remission.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, China · NCT06835140

• Combining avapritinib, azacitidine, and venetoclax for treating relapsed AML after stem cell transplant

  This study is testing a new combination of three medications to see if they can help people with relapsed acute myeloid leukemia feel better after a stem cell transplant.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06783790

• Combining Venetoclax with Intensive Chemotherapy for Acute Myeloid Leukemia

  This study is testing if adding Venetoclax to strong chemotherapy helps adults with Acute Myeloid Leukemia feel better and which genetic types benefit the most from this treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06635681

Related topics

Quick answers

How many AML (Acute Myelogenous Leukemia) clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (8 trials), Italy (2 trials), United Kingdom (1 trial), Russia (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 2: 3, Early Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →